Objective We studied evolving antithrombotic therapy patterns in patients with newly
diagnosed non-valvular atrial fibrillation (AF) and≥ 1 additional stroke risk factor between …

Objective To investigate evolving patterns in antithrombotic treatment in UK patients with
newly diagnosed non-valvular atrial fibrillation (AF). Design Prospective, multicentre …

Introduction A principal aim of the Global Anticoagulant Registry in the FIELD-Atrial
Fibrillation (GARFIELD-AF) was to document changes in treatment practice for patients with …

Aims The introduction of non-VKA oral anticoagulants (NOACs), which differ from the earlier
vitamin K antagonist (VKA) treatments, has changed the approach to stroke prevention in …

Abstract Background The Global Registry on Long-Term Oral Antithrombotic Treatment in
Patients with Atrial Fibrillation (GLORIA-AF) was designed to provide prospectively collected …

Abstract Aims Oral anticoagulants (OACs) effectively reduce the risk of stroke in atrial
fibrillation (AF). Three non-vitamin K antagonist OACs (NOACs) are introduced in regular …

Objectives To describe (i) the trend in oral anticoagulant (OAC) use following the
introduction of non-vitamin K antagonist oral anticoagulant (NOAC) therapy for stroke …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe
alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention in …

Efforts to reduce stroke in atrial fibrillation (AF) have focused on increasing physician
adherence to oral anticoagulant (OAC) guidelines, but high early vitamin K antagonist (VKA) …

Objective Atrial fibrillation (AF) is the most common cardiac arrhythmia and an important risk
factor for stroke. Treatment with anticoagulants substantially reduces risk of stroke. Current …